{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:55:11Z","timestamp":1760550911572,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T00:00:00Z","timestamp":1566345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T00:00:00Z","timestamp":1566345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s40262-019-00812-x","type":"journal-article","created":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T04:46:18Z","timestamp":1566362778000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?"],"prefix":"10.1007","volume":"59","author":[{"given":"Didier","family":"Concordet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy","family":"Gandia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Louis","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Bousquet-M\u00e9lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Lees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude A.","family":"Ferran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8846-8892","authenticated-orcid":false,"given":"Pierre-Louis","family":"Toutain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,21]]},"reference":[{"key":"812_CR1","unstructured":"Merck. Merck receives recommendation for approval in 21 EU countries for the new formulation of Euthyrox\u00ae. \nhttps:\/\/www.merckgroup.com\/en\/news\/euthyrox-approval-eu-26-07-2018.html\n\n. Accessed 16 Aug 2018."},{"key":"812_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/03007995.2016.1246434","volume":"33","author":"U Gottwald-Hostalek","year":"2017","unstructured":"Gottwald-Hostalek U, Uhl W, Wolna P, Kahaly GJ. New levothyroxine formulation meeting 95\u2013105% specification over the whole shelf-life: results from two pharmacokinetic trials. Curr Med Res Opin. 2017;33:169\u201374.","journal-title":"Curr Med Res Opin."},{"key":"812_CR3","unstructured":"\u201cEnqu\u00eate de pharmacovigilance Levothyrox\u00ae\u201d levothyroxine. Laboratoire Merck. Enqu\u00eate officielle (3eme presentation). Rapport du 04\/07\/2018. ANSES. \nhttps:\/\/ansm.sante.fr\/var\/ansm_site\/storage\/original\/application\/73c1a2f8f97a5fd351f4196ed1d68b1a.pdf\n\n. Accessed 16 Aug 2018."},{"key":"812_CR4","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.therap.2019.01.003","volume":"74","author":"S Mouly","year":"2019","unstructured":"Mouly S, Roustit M, Bagheri H, Perault-Pochat M-C, Molimard M, Bordet R. The French Levothyrox\u00ae crisis: we did the best we could but\u2026. Therapie. 2019;74:431\u20135.","journal-title":"Therapie."},{"key":"812_CR5","unstructured":"Levothyrox et m\u00e9dicaments \u00e0 base de l\u00e9vothyroxine: rapport final de l\u2019\u00e9tude de pharmaco-\u00e9pid\u00e9miologie \u00e0 partir des donn\u00e9es du Syst\u00e8me National des Donn\u00e9es de Sant\u00e9 (SNDS) - Point d\u2019Information - ANSM\u202f: Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9. 2019. \nhttps:\/\/www.ansm.sante.fr\/S-informer\/Actualite\/Levothyrox-et-medicaments-a-base-de-levothyroxine-Rapport-final-de-l-etude-de-pharmaco-epidemiologie-a-partir-des-donnees-du-Systeme-National-des-Donnees-de-Sante-SNDS-Point-d-Information\n\n. Accessed 24 Jun 2019."},{"key":"812_CR6","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1528-1167.2007.01007.x","volume":"48","author":"F Andermann","year":"2007","unstructured":"Andermann F, Duh MS, Gosselin A, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia. 2007;48:464\u20139.","journal-title":"Epilepsia."},{"key":"812_CR7","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s40262-019-00747-3","volume":"58","author":"D Concordet","year":"2019","unstructured":"Concordet D, Gandia P, Montastruc JL, Bousquet-M\u00e9lou A, Lees P, Ferran A, et al. Levothyrox\u00ae new and old formulations: are they switchable for millions of patients? Clin Pharmacokinet. 2019;58:827\u201333.","journal-title":"Clin Pharmacokinet."},{"key":"812_CR8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/BF01062202","volume":"18","author":"S Anderson","year":"1990","unstructured":"Anderson S, Hauck WW. Consideration of individual bioequivalence. J Pharmacokinet Biopharm. 1990;18:259\u201373.","journal-title":"J Pharmacokinet Biopharm."},{"key":"812_CR9","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/BF02353794","volume":"22","author":"WW Hauck","year":"1994","unstructured":"Hauck WW, Anderson S. Measuring switchability and prescribability: when is average bioequivalence sufficient? J Pharmacokinet Biopharm. 1994;22:551\u201364.","journal-title":"J Pharmacokinet Biopharm."},{"key":"812_CR10","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Guideline on the investigation of bioequivalence. European Medicines Agency; 2010. \nhttps:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-bioequivalence-rev1_en.pdf\n\n. Accessed 10 Aug 2019."},{"key":"812_CR11","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1345\/aph.1M141","volume":"43","author":"BM Davit","year":"2009","unstructured":"Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, et al. Comparing generic and innovator drugs: a review of 12\u00a0years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother. 2009;43:1583\u201397.","journal-title":"Ann Pharmacother."},{"issue":"2","key":"812_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s10928-019-09623-w","volume":"46","author":"L Endrenyi","year":"2019","unstructured":"Endrenyi L, Tothfalusi L. Bioequivalence for highly variable drugs: regulatory agreements, disagreements, and harmonization. J Pharmacokinet Pharmacodyn. 2019;46(2):117\u201326.","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"812_CR13","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/cpt.28","volume":"97","author":"L Yu","year":"2015","unstructured":"Yu L, Jiang W, Zhang X, Lionberger R, Makhlouf F, Schuirmann D, et al. Novel bioequivalence approach for narrow therapeutic index drugs. Clin Pharmacol Ther. 2015;97:286\u201391.","journal-title":"Clin Pharmacol Ther."},{"issue":"1","key":"812_CR14","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/cpt.1353","volume":"106","author":"G Van Lancker","year":"2019","unstructured":"Van Lancker G, Van Bortel L, Delafontaine B, Boussery K, Swart E, Chahbouni A, et al. Switchability of gabapentin formulations: a randomized trial to assess bioequivalence between neurontin and gabasandoz on the individual subject level. Clin Pharmacol Ther. 2019;106(1):195\u2013203.","journal-title":"Clin Pharmacol Ther."},{"key":"812_CR15","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/cpt.1293","volume":"105","author":"P Jayachandran","year":"2019","unstructured":"Jayachandran P, Okochi H, Frassetto LA, Park W, Fang L, Zhao L, et al. Evaluating within-subject variability for narrow therapeutic index drugs. Clin Pharmacol Ther. 2019;105:411\u20136.","journal-title":"Clin Pharmacol Ther."},{"key":"812_CR16","unstructured":"US FDA. Draft guidance on levothyroxine sodium. Food & Drug Administration; 2018. p. 2. \nhttps:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM428208.pdf\n\n. Accessed 4 Oct 2019."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00812-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-019-00812-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00812-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T16:39:58Z","timestamp":1600274398000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-019-00812-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,21]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["812"],"URL":"https:\/\/doi.org\/10.1007\/s40262-019-00812-x","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"type":"print","value":"0312-5963"},{"type":"electronic","value":"1179-1926"}],"subject":[],"published":{"date-parts":[[2019,8,21]]},"assertion":[{"value":"21 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Didier Concordet, Peggy Gandia, Jean-Louis Montastruc, Alain Bousquet-M\u00e9lou, Peter Lees, Aude A. Ferran, and Pierre-Louis Toutain declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}